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Allogeneic hematopoietic cell transplantation (HCT) offers curative therapy for many patients with myelo-
dysplastic syndrome (MDS) or acute myeloid leukemia (AML). However, post-HCT relapse remains a major
problem, particularly in patients with high-risk cytogenetics. In this prospective phase II trial, we assessed the
efﬁcacy and toxicity of treosulfan, ﬂudarabine, and 2 Gy total body irradiation (TBI) as conditioning for
allogeneic HCT in patients with MDS or AML. Ninety-six patients with MDS (n ¼ 36: 15 refractory cytopenia
with multilineage dysplasia, 10 refractory anemia with excess blasts type 1, 10 refractory anemia with excess
blasts type 2, 1 chronic myelomonocytic leukemia type 1) or AML (n ¼ 60: 35 ﬁrst complete remission [CR],
18 second CR, 3 advanced CR, 4 refractory relapse) were enrolled; median age was 51 (range, 1 to 60) years.
Twelve patients had undergone a prior HCT with high-intensity conditioning. Patients received 14 g/m2/day
treosulfan i.v. on days 6 to 4, 30 mg/m2/day ﬂudarabine i.v. on days 6 to 2, and 2 Gy TBI on day 0,
followed by infusion of hematopoietic cells from related (n ¼ 27) or unrelated (n ¼ 69) donors. Graft-versus-
host disease prophylaxis consisted of tacrolimus and methotrexate. With a median follow-up of 30 months,
the 2-year overall survival (OS), relapse incidence, and nonrelapse mortality were 73%, 27%, and 8%,
respectively. The incidences of grades II to IV (III to IV) acute and chronic graft-versus-host disease were 59%
(10%) and 47%, respectively. Two-year OS was not signiﬁcantly different between MDS patients with poor-risk
and good/intermediate-risk cytogenetics (69% and 85%, respectively) or between AML patients with unfa-
vorable and favorable/intermediate-risk cytogenetics (64% and 76%, respectively). In AML patients, minimal
residual disease (MRD; n ¼ 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and
lower OS (41% versus 79%) at 2 years, when compared with patients without MRD. In conclusion, treosulfan,
ﬂudarabine, and low-dose TBI provided effective conditioning for allogeneic HCT in patients with MDS or
AML and resulted in low relapse incidence, regardless of cytogenetic risk. In patients with AML, MRD at the
time of HCT remained a risk factor for post-HCT relapse.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The median patient age at diagnosis of myelodysplastic
syndromes (MDS) is in the mid-70s [1] and for acute myeloid
leukemia (AML) in the mid-to-late 60s (SEER statistics, 2005ual meeting of the American Society of
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Allogeneic hematopoietic cell transplantation (HCT) after
high-dose conditioning has curative potential but is associ-
ated with high rates of treatment-related morbidity and
mortality, particularly in older patients. Reduced-intensity
conditioning regimens, which rely more on immunologic
graft-versus-leukemia effects for tumor eradication, have
been associated with less toxicity [2-16]; however, post-HCT
relapse tends to be more frequent than with high-intensity
regimens. In fact, among patients with MDS and AML condi-
tioned with reduced-intensity regimens, the leading cause of
treatment failure has been relapse, with a 2- to 4-yearTransplantation.
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that are associatedwith low relapse incidence and nonrelapse
mortality (NRM).
Treosulfan (Ovastat, L-treitol-1,4-bis-methanesulfonate,
dihydroxybusulfan; Medac, Hamburg, Germany) is a water-
soluble prodrug of a bifunctional alkylating agent approved
in European countries for the treatment of advanced ovarian
carcinoma. In contrast to busulfan, treosulfan does not re-
quire enzymatic activation, thus bypassing hepatic meta-
bolism. Also, pharmacokinetic studies of both single-dose
andmultiple intravenous infusions of treosulfan have shown
low interpatient and intrapatient variability. The dose-
limiting toxicity at 10 g/m2 was marrow suppression, sug-
gesting the drug might be useful for HCT conditioning.
In vitro studies showed strong proapoptotic effects in human
AML cells [18], and murine xenograft models demonstrated
potent in vivo activity of treosulfan against human B cell
and T cell lymphoblast cell lines [19] and various solid
tumors, myeloma, lymphoma, and acute and chronic leu-
kemias [18-20]. Murine transplant models also showed
pronounced effects of treosulfan on primitive and com-
mitted hematopoietic cells and immunosuppressive activity
[21]. In clinical trials, using autologous stem cell rescue, the
maximum tolerated treosulfan dose could be escalated from
10 to 47 g/m2 (cumulative dose) before mucositis, diarrhea,
dermatitis, or metabolic acidosis proved to be dose limiting
[22]. No severe hepatotoxicity or central nervous system
toxicity was seen.
Similar to clinical studies from several European centers
reporting high engraftment rates, low NRM, and improved
survival with treosulfan-based conditioning regimens for
allogeneic HCT [23,24], we observed encouraging results in a
phase I/II multi-institution trial using escalating doses of
treosulfan (36 to 42 g/m2) in combination with ﬂudarabine
(150 mg/m2) in 60 patients with MDS or acute leukemia [25].
The 2-year cumulative incidences of relapse and NRM were
33% and 8.3%, respectively. Although the 2-year progression-
free survival rate was 88% in patients with favorable- or
intermediate-risk cytogenetics, it was 39% among patients
with unfavorable-risk cytogenetics, primarily due to a
relapse incidence of 43% at 2 years.
Here, we report outcomes of a subsequent phase II
multicenter trial in which low-dose (2 Gy) total body irra-
diation (TBI) was added to the treosulfan/ﬂudarabine re-
gimen, with the goal of reducing the incidence of relapse in
patients with high-risk cytogenetics without compromising
the favorable toxicity proﬁle. The rationale for adding TBI to
the regimen was based on preclinical data indicating that
treosulfan had radiosensitizing properties [26], suggesting
the possibility that the interaction between treosulfan and
TBI would lead to enhanced leukemic cell kill. This was
feasible because the treosulfan/ﬂudarabine regimen was
associated with minimal toxicity. However, because the
clinical toxicity proﬁle of such a regimen, including TBI, had
not been determined previously, eligibility was restricted to
patients 60 years of age or younger.METHODS
Between February 2009 and July 2012, 96 patients were enrolled at
the Fred Hutchinson Cancer Research Center, Seattle, Washington
(which served as the coordinating center), Oregon Health and Science
University, Portland, and the University of Colorado Denver, Denver. The
protocol was approved by institutional review boards at all centers and
was registered at www.clinicaltrials.gov as NCT00860574. All patients
signed informed consent forms approved by local institutional review
boards.Eligibility
Eligibility criteria were as follows: (1) intermediate- or unfavorable-risk
AML in ﬁrst complete remission (CR1), AML beyond CR1, or MDS in any risk
group (in AML patients, cytogenetic risk was classiﬁed by Southwest
Oncology Group criteria [27], in MDS patients by International Prognostic
Scoring System criteria [28]); (2) age 60 years or younger; (3) Karnofsky
score 70% or higher; and (4) availability of HLA-matched related or unrelated
donor. Related donors were matched by intermediate resolution molecular
typing for HLA-A, -B, -C, and -DQB1 and by high-resolution typing for -DRB1.
Unrelated donors were allele matched for HLA-A, -B, -C, and -DRB1 by high-
resolution typing and for -DQB1 by intermediate resolution typing; a single
allele-level mismatch was allowed. Patients with recurrent disease after
previous autologous or allogeneic HCT were eligible.
Patients were excluded for the following reasons: (1) impaired cardiac
function (ejection fraction <35%), treatment-dependent cardiac insufﬁ-
ciency, or symptomatic coronary artery disease; (2) impaired pulmonary
function (PO2 < 70 mm Hg and DLCO < 70% of predicted) or requiring
supplementary oxygen; (3) creatinine clearance < 50% of predicted or
requiring dialysis; (4) total bilirubin, aspartate aminotransferase or alanine
aminotransferase >2 times upper limit of normal, evidence of synthetic
dysfunction, or cirrhosis; (5) HIV positivity or active hepatitis; and (6)
central nervous system involvement (persistent despite intrathecal
chemotherapy or cranial irradiation).
CR of AML was deﬁned by standard morphologic criteria [29];
morphologic CR with incomplete blood count recovery (absolute neutrophil
count <1000/mL or platelet count <100,000/mL) was included. Minimal re-
sidual disease (MRD) was assessed by multiparameter ﬂow cytometry as
described previously [30], karyotype analysis, and ﬂuorescence in situ hy-
bridization, when applicable, performed within 30 days before HCT.
Conditioning Regimen, Stem Cell Source, Graft-versus-Host Disease
Prophylaxis, and Supportive Care
Patients received treosulfan i.v. on days6 to4 at doses of 14 g/m2/day
(total 42 g/m2) [22] and ﬂudarabine i.v. on days 6 to 2 at doses of 30 mg/
m2/day (total 150 mg/m2). A single dose of 2 Gy TBI was delivered from a
linear accelerator on day 0, followed by infusion of donor cells. The preferred
source of hematopoietic cells was granulocyte colony-stimulating fac-
toremobilized peripheral blood stem cells, but marrow was allowed when
peripheral blood stem cells were not available.
Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus
and methotrexate, as described [31]. Supportive care was provided as pre-
viously described [32]. All patients received prophylactic ursodiol for
90 days post-HCT [33].
Post-HCT Monitoring, Engraftment, and GVHD
Patients underwent diagnostic marrow aspirations on days 28, 84, and
360 after HCT, or when clinically indicated, to assess disease status. Donor
chimerism was evaluated in peripheral blood T cells, granulocytes, and un-
sortedmarrow cells on days 28, 84, and 360, respectively, after HCT. The time
of myeloid engraftment was deﬁned as the ﬁrst of 3 consecutive days with
absolute neutrophil counts .5  109/L. Platelet engraftment was deﬁned as
the ﬁrst of 7 consecutive dayswith untransfused platelet counts>20 109/L.
Acute and chronic GVHD were graded and treated as described [34,35].
Causes of Death
Relapse-related mortality was deﬁned as death after relapse or disease
progression, regardless of other events; NRM included all deaths without
relapse or disease progression. GVHD mortality included all nonrelapse
deaths in patients with GVHD, regardless of the immediate cause.
Statistical Analysis
Survival was estimated by the Kaplan-Meier method. Cumulative inci-
dence curves were estimated by methods previously described [36]. Death
was treated as a competing risk in the analysis of relapse, acute GVHD, and
chronic GVHD. Relapse was treated as a competing risk in the analysis of
NRM. Cox regression was used to evaluate covariate associations with the
hazards of overall mortality, NRM, and relapse. All P values refer to hazard
ratio analyses, are 2-sided, and are derived from likelihood ratio tests. Data
were analyzed as of December 3, 2013.
RESULTS
Patient Characteristics
Patient and disease characteristics are summarized in
Table 1. Ninety-six patients, median age 51 years (range, 1 to
60), were enrolled. Thirty-six patients (38%) had MDS,
including 1 patient with chronic myelomonocytic leukemia,
Table 1
Patient (N ¼ 96) and Disease Characteristics
Characteristics n
Median age, yr (range) 51 (1-60)
Diagnosis
MDS 36
AML 60
Cytogenetics
Favorable/good 14
Intermediate/undetermined signiﬁcance 39
Unfavorable/poor 43
MDS type: De novo 25
Secondary* 11
Stage: RCMD 15
RAEB-1 10
RAEB-2 10
CMML-1 1
Cytogenetic risk (IPSS): Good 11
Intermediate 9
Poor 16
IPSS risk category: Low 3
Intermediate-1 9
Intermediate-2 22
High 2
AML type: De novo 45
Secondaryy 15
Stage: CR1 (MRD present) 35 (3)
CR2 (MRD present) 18 (6)
Advanced CR (MRD present) 3 (1)
Relapse/refractory 4
Cytogenetic risk: Favorable 3
Intermediate 28
Unfavorable 27
Undetermined prognostic signiﬁcance 2
Donor
HLA-identical sibling 27
HLA-matched unrelated (1 HLA-allele mismatch) 69 (10)
Stem cell source
Marrow 12
PBSC 84
Previous HCT with high-dose conditioning (allogeneic) 12 (8)
Median follow-up, mo (range) 22 (6-44)
Durable engraftment, % 100
RCMD indicates refractory cytopenia with multilineage dysplasia; RAEB,
refractory anemia with excess blasts; CMML, chronic myelomonocytic
leukemia; IPSS, International Prognostic Scoring System; CR2, second
complete remission; PBSC, peripheral blood stem cells.
* MDS was therapy-related in 10 patients and evolved from paroxysmal
nocturnal hemoglobinuria in 1.
y AML was therapy-related in 7 patients and evolved from MDS in 8.
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HCTs (8 allogeneic, 4 autologous) after high-dose condi-
tioning regimens.
Engraftment and GVHD
Two patients died before day 28 (day 4, cardiogenic
shock; day 21, septic shock) and were not assessable forFigure 1. Cumulative incidence of GVHD: (A) acute, grengraftment. The remaining 94 patients achieved neutrophil
engraftment at a median of 18 days (range, 10 to 40) and
platelet engraftment at a median of 17 days (range, 9 to 88).
Median donor CD3 þ T lymphocyte chimerism in peripheral
blood on days 28 and 84 was 100% (range, 88% to 100%) and
100% (range, 61% to 100%), respectively. No graft rejections
occurred.
The median onset of acute GVHD was day 28 (range, 11 to
112) after HCT. The cumulative incidence of grades II to IV (III
to IV) acute GVHD was 59% (10%) (Figure 1A). Extensive
chronic GVHD developed in 47% of patients at a median of
201 days (range, 86 to 715) (Figure 1B). There was no sta-
tistically signiﬁcant difference between related and unre-
lated donor transplants, although there was a trend toward
higher incidence of chronic GVHD in patients with unrelated
donors (51% versus 34% in patients with related donors;
P ¼ .11).Survival, Progression-Free Survival, Relapse/Progression,
and Relapse-Related Mortality
As of December 3, 2013, the median follow-up of sur-
viving patients was 30 months (range, 12 to 50) months, and
69 patients (72%) were alive. The estimated overall survival
(OS) at 2 years was 73% for the entire cohort and 77% and
71%, respectively, for patients with MDS and AML (Figure 2).
Progression-free survival at 2 years was 64% for the whole
cohort. The estimated 2-year relapse incidence was 27%
(Figure 2). The relapse incidence in patients with unfavor-
able cytogenetics did not differ signiﬁcantly from that in
patients with favorable/intermediate-risk cytogenetics (28%
versus 27%; P¼ .77; Figure 3A), and there was no statistically
signiﬁcant difference in OS (66% versus 79%; P ¼ .18;
Figure 3B).
Among 26 patients who relapsed, 19 died; 7 patients who
had relapsed remained alive in CR at last follow-up, after
rapid taper of immunosuppression (n ¼ 4), administration
of azacitidine (n ¼ 4), adoptive immunotherapy with CD8 þ
WT1-speciﬁc cytotoxic lymphocytes (n ¼ 3), donor
lymphocyte infusion (n¼ 1), a second allogeneic HCT (n¼ 1),
local radiation to site of extramedullary relapse (n ¼ 1), or
combinations thereof. Outcomewas similar for patients with
HLA-identical related and HLA-matched unrelated donors
(2-year OS 73% versus 73%; relapse incidence 33% versus
25%; NRM 7% versus 9%, respectively).
When the analysis was restricted to patients with MDS,
cytogenetic risk, (good/intermediate, n ¼ 20, versus poor,
n ¼ 16), International Prognostic Scoring System risk (low/
intermediate-1, n ¼ 12, versus intermediate-2/high, n ¼ 24),
or marrow blast content (<10%, n ¼ 26, versus 10%, n ¼ 10)
had no statistically signiﬁcant impact on relapse or OSades II-IV and III-IV, and (B) chronic, extensive.
Figure 2. OS, relapse mortality, and NRM (N ¼ 96).
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low number of events were limiting factors. The 2-year
relapse incidence was 20% (25% for good/intermediate-risk
versus 13% for poor-risk cytogenetics, P ¼ .37), and OS was
77% (85% for good/intermediate-risk versus 69% for poor-risk
cytogenetics; P ¼ .53; Figure 3C,D). Categorization of MDS
patients on the basis of the 5-group cytogenetic risk classi-
ﬁcation described by Schanz et al. [37] resulted in too fewFigure 3. Cytogenetics and outcome for (A and B) all patients, (C and D) papatients in the very good and very poor risk groups to allow
for a meaningful statistical analysis (not shown).
Among AML patients with favorable/intermediate-risk
versus unfavorable cytogenetics, the 2-year relapse inci-
dence was 27% versus 38%, respectively, with corresponding
OS rate estimates of 76% and 64%, respectively (Figure 3E,F).
The only pre-HCT characteristic with statistically signiﬁcant
impact on post-HCT relapse was the presence of MRD, with
an incidence of 70% versus 18% in patients without MRD
(P ¼ .002; Figure 4A). Excluding the 4 patients in morpho-
logic relapse at the time of HCT, these ﬁgures translated into
2-year OS rates of 80% (patients without MRD) and 47%
(patients with MRD) (P ¼ .12; Figure 4D). Three of the 4 pa-
tients in refractory relapse at the time of HCT died with
progressive disease (on days 47, 177, and 375, respectively).
The fourth patient showed MRD on day 81 (.1% by ﬂow
cytometry) but entered CR after monthly administration of
azacitidine and remained in remission at last follow-up,
more than one year after HCT.Toxicity and NRM
Day 100 nonhematologic toxicities are summarized in
Table 2. Grades 3 and 4 mucositis developed in 23 and 4
patients, respectively. Ten patients showed extensive but self-
limited erythematous skin rashes. Four patients with grade
4 mucositis required temporary endotracheal intubation fortients with MDS (n ¼ 36), and (E and F) patients with AML (n ¼ 60).
Figure 4. Pretransplant MRD and relapse (A) and survival (B) in patients with AML in morphologic remission (n ¼ 56).
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curred. Two of these four patients had previously undergone
HCT with high-dose conditioning, and two had received
intensive cytoreductive therapy.
The cumulative incidence of NRM at day 100, 6 months,
and 2 years was 3%, 6%, and 8%, respectively. Causes of death
included GVHD (n ¼ 6) and infection/multiorgan failure
(n ¼ 2). Two of 8 patients who died of nonrelapse causes had
previously undergone HCT with high-dose conditioning. Of
the 12 patients with previous HCT, 8 remained in remission
at last follow-up, whereas 4 died from relapse (n ¼ 2),
multiorgan failure (n ¼ 1), or GVHD (n ¼ 1).
DISCUSSION
This study was designed to evaluate the safety and efﬁ-
cacy of adding 2 Gy TBI to a conditioning regimen of treo-
sulfan and ﬂudarabine, followed by allogeneic HCT in
patients with MDS or AML. The major ﬁndings were as fol-
lows: (1) the incidence of relapse in patients with unfavor-
able cytogenetic risk was not statistically signiﬁcantly
different from that in patients with favorable/intermediateTable 2
Grade 3-5 Nonhematologic Toxicity Between Initiation of Conditioning and
Day 100 Post-HCT
Organ System No. of Events*
Grade
3
Grade
4
Grade
5
Infectiony 39 6 3
Mucositis 23 4 0
Gastrointestinal (anorexia, nausea, vomiting,
diarrhea)
19 0 0
Hepaticz (SOS: n ¼ 0) 6 0 0
Dermatology/skin (drug-related rash,
erythema)
10 0 0
Cardiac 3 0 1
Pulmonary 7 1 0
Renalx 3 1 0
Coagulation (DVT/PE, TTP, retinal vein
occlusion)
3 0 0
CNS (PRES: n ¼ 2) 4 0 0
No. of patients with any event 51 4 4
SOS indicates sinusoidal obstruction syndrome; DVT, deep vein thrombosis;
PE, pulmonary embolism; CNS, central nervous system; PRES, posterior
reversible encephalopathy syndrome.
* According to Common Terminology Criteria for Adverse Events 4.0 (http://
evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).
y Grade 3 infections included episodes of cytomegalovirus reactivation
(n ¼ 15) and neutropenic fever (n ¼ 9).
z Grade 3 hepatic toxicity consisted of transient elevations of hepatic
transaminases.
x Grade 4 renal toxicity included rejection of a pre-existing renal graft and
reinitiation of hemodialysis.cytogenetic risk; (2) in patients with AML, the presence of
MRD predicted higher relapse incidence and inferior OS
compared with patients without MRD; and (3) the addition
of 2 Gy TBI altered the toxicity proﬁle but did not result in
increased NRM [24,25,38].
Although the generally low number of relapse events
limited the power of the analysis, the low relapse incidence
among patients with unfavorable cytogenetic risk, which
was similar to that in patients with favorable karyotype, was
an intriguing observation. These results, which need to be
conﬁrmed in follow-up studies, suggest that treosulfan may
be beneﬁcial in overcoming, at least in part, the formidable
barrier of high-risk cytogenetics. The data also support
the concept that unrecognized risk factors, and, hence, not
considered in current classiﬁcation schemes, play an im-
portant role in HCT outcome. Future trials, both in patients
withMDS and AML, will need to include analyses of currently
known and suspected mutations and gene expression pro-
ﬁles. The observed impact of MRD on relapse in patients with
AML suggests, furthermore, that disease risk, as measured by
the leukemic cell burden, carries a different weight from
cytogenetic markers and that both must be considered in the
design of novel trials [30,39]. However, it remains to be
determined whether it is, indeed, the pretransplant tumor
burden that is associated with higher relapse risk or whether
the presence of MRD is a marker of intrinsically more
aggressive disease.
The treosulfan/ﬂudarabine/TBI regimen described here
was well tolerated, with a NRM of 8% at 2 years. It may
therefore be possible to further intensify the regimen in
patients with high-risk disease, although the toxicity proﬁle
did differ from that observed in patients conditioned with
treosulfan and ﬂudarabine without TBI [25] or in patients
undergoing conditioning with ﬂudarabine and 2 Gy TBI [40].
In particular, higher incidence of grades 3 and 4 mucositis
and of cutaneous toxicity (self-limited, indolent erythema)
were seen, consistent with preclinical data, which suggest a
radiosensitizing effect of treosulfan [26]. It is intriguing to
speculate that such a radiosensitizing effect was also bene-
ﬁcial in reducing the relapse rate in patients with high-risk
cytogenetics. The net result of the reduced relapse inci-
dence was an increased probability of OS among patients
with high-risk cytogenetics which approached that of pa-
tients with favorable cytogenetics. However, the present
regimen failed to improve results in AML patients with MRD,
similar to previous studies using other regimens [30], sug-
gesting the impact of disease burden on the outcome of HCT
is different from the impact of cytogenetic risk.
Direct comparisons with historical data are difﬁcult
because of differences in patient populations and disease
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supportive care over the years may contribute to favorable
outcome, several studies found improved OS with
treosulfan-based conditioning in comparison with historical
data [24,41-43]. In patients with MDS or AML conditioned
with treosulfan/ﬂudarabine and transplanted from HLA-
matched related or unrelated donors, Ruutu et al. [38]
showed 2-year NRM of 17% and OS of 71% and Casper et al.
[24] showed 2-year NRM of 11% and OS of 61%. We interpret
our results as evidence that the addition of 2 Gy TBI did not
compromise the favorably low toxicity proﬁle associated
with treosulfan/ﬂudarabine, but, apparently, did beneﬁt pa-
tients with high-risk cytogenetics.
Results with the current regimen compare favorably with
results achieved with high-dose, targeted busulfan and
cyclophosphamide regimens, which are used widely in pa-
tients transplanted for MDS and AML. We reported previ-
ously 3-year progression-free survival rates of 56% to 59% in
patients with MDS, who were slightly younger than patients
in the current study (median age, 46 years versus 51 years)
and fewer of whom had high-risk cytogenetics (27% versus
45%) [44]. However 3-year NRM was 28% to 30% compared
with 8% (at 2 years) in the current study. In a randomized
trial comparing conditioning with busulfan plus cyclophos-
phamide with a combination of busulfan plus ﬂudarabine in
patients with leukemia (including acute lymphoblastic leu-
kemia and CML) and MDS, Lee et al. [45] showed a 2-year OS
rate of 67% in the busulfan/cyclophosphamide arm (versus
41.4% in the busulfan/ﬂudarabine arm), similar to the present
results. However, patients were, on average,10 years younger
(median age, 41 versus 51 years) and only 28% had poor-risk
cytogenetics. These comparisons support the concept that
treosulfan-based regimens may offer a two-fold advantage,
that is, excellent regimen tolerability, even in older patients,
and therapeutic efﬁcacy in high-risk disease [46]. However,
no prospective studies have been conducted comparing, for
example, a treosulfan-based regimenwith targeted busulfan
plus cyclophosphamide (or ﬂudarabine plus busulfan).
In summary, a regimen of treosulfan, ﬂudarabine, and
low-dose TBI was well tolerated and offered effective con-
ditioning for allogeneic HCT in patients up to 60 years of
age with MDS or AML in CR at the time of HCT. The favorable
toxicity proﬁle and low NRM make this regimen potentially
applicable to older patients in future trials. Relapse incidence
and OS in patients with high-risk cytogenetics did not differ
signiﬁcantly from outcome in patients with favorable/inter-
mediate-risk karyotypes. The relapse incidence was partic-
ularly low in patients with MDS. However, in patients with
AML with MRD at the time of HCT the relapse incidence was
high, suggesting that high risk deﬁned by MRD had a
different impact on outcome than high risk deﬁned by kar-
yotype. Alternative conditioning strategies, such as radio-
immunotherapy [47], should be considered for these disease
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